Revvity (RVTY) Upgraded to Buy: What Does It Mean for the Stock?
Revvity (RVTY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Strength Seen in Revvity (RVTY): Can Its 9.1% Jump Turn into More Strength?
Revvity (RVTY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Revvity, Inc. (RVTY) Presents at 2026 Global Healthcare Conference Transcript
Revvity, Inc. (RVTY) Presents at 2026 Global Healthcare Conference Transcript
Revvity to Acquire Human Cell Design to Boost Metabolic Discovery
RVTY's HCD deal is expected to add human pancreatic beta cell models, expanding drug discovery and preclinical research tools for metabolic diseases.
Why Revvity (RVTY) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich?
Revvity's raised 2026 outlook, Diagnostics growth and stronger cash flow brighten the setup, but premium valuation and software risks call for selectivity.
What Makes Revvity (RVTY) a New Buy Stock
Revvity (RVTY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is the Options Market Predicting a Spike in Revvity Stock?
Investors need to pay close attention to RVTY stock based on the movements in the options market lately.
Revvity Launches SuperFlex Prenatal Screening System for Smaller Labs
RVTY launches SuperFlex, a compact automated prenatal screening system aimed at expanding rapid in-house testing for smaller labs and clinics.
Revvity Q2 Earnings Call Highlights
Revvity NYSE: RVTY reported second-quarter results above its expectations and raised its full-year outlook, citing continued strength in diagnostics, improving demand from pharmaceutical and biotechnology customers, and growing orders tied to artificial intelligence-enabled drug discovery workflows.
RVTY Q2 Earnings Beat Estimates on Diagnostics Strength, '26 View Up
Revvity beats Q2 earnings and sales estimates as Diagnostics growth, wider margins and strong cash flow support a higher 2026 outlook.
Revvity (RVTY) Q2 Earnings and Revenues Surpass Estimates
Revvity (RVTY) came out with quarterly earnings of $1.41 per share, beating the Zacks Consensus Estimate of $1.23 per share. This compares to earnings of $1.18 per share a year ago.
